187 related articles for article (PubMed ID: 25794004)
1. Vascular pattern analysis for the prediction of clinical behaviour in pheochromocytomas and paragangliomas.
Oudijk L; van Nederveen F; Badoual C; Tissier F; Tischler AS; Smid M; Gaal J; Lepoutre-Lussey C; Gimenez-Roqueplo AP; Dinjens WN; Korpershoek E; de Krijger R; Favier J
PLoS One; 2015; 10(3):e0121361. PubMed ID: 25794004
[TBL] [Abstract][Full Text] [Related]
2. Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism.
Tevosian SG; Ghayee HK
J Clin Endocrinol Metab; 2018 May; 103(5):1779-1789. PubMed ID: 29409060
[TBL] [Abstract][Full Text] [Related]
3. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
[TBL] [Abstract][Full Text] [Related]
4. Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.
Gimm O; DeMicco C; Perren A; Giammarile F; Walz MK; Brunaud L
Langenbecks Arch Surg; 2012 Feb; 397(2):155-77. PubMed ID: 22124609
[TBL] [Abstract][Full Text] [Related]
5. Intra-tumoral molecular heterogeneity in benign and malignant pheochromocytomas and extra-adrenal sympathetic paragangliomas.
Korpershoek E; Stobbe CK; van Nederveen FH; de Krijger RR; Dinjens WN
Endocr Relat Cancer; 2010 Sep; 17(3):653-62. PubMed ID: 20488782
[TBL] [Abstract][Full Text] [Related]
6. Pheochromocytomas and paragangliomas in humans and dogs.
Galac S; Korpershoek E
Vet Comp Oncol; 2017 Dec; 15(4):1158-1170. PubMed ID: 28120550
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas.
Amorim-Pires D; Peixoto J; Lima J
Cytogenet Genome Res; 2016; 150(3-4):227-241. PubMed ID: 28231563
[TBL] [Abstract][Full Text] [Related]
8. Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma/paraganglioma.
Lee SE; Oh E; Lee B; Kim YJ; Oh DY; Jung K; Choi JS; Kim J; Kim SJ; Yang JW; An J; Oh YL; Choi YL
Oncotarget; 2016 Apr; 7(17):24141-53. PubMed ID: 27007161
[TBL] [Abstract][Full Text] [Related]
9. [Tumors of the adrenal medulla and the paraganglia].
Klöppel G
Pathologe; 2003 Jul; 24(4):280-6. PubMed ID: 14513275
[TBL] [Abstract][Full Text] [Related]
10. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
Guo Z; Lloyd RV
Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
[TBL] [Abstract][Full Text] [Related]
11. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways.
de Cubas AA; Leandro-García LJ; Schiavi F; Mancikova V; Comino-Méndez I; Inglada-Pérez L; Perez-Martinez M; Ibarz N; Ximénez-Embún P; López-Jiménez E; Maliszewska A; Letón R; Gómez Graña A; Bernal C; Alvarez-Escolá C; Rodríguez-Antona C; Opocher G; Muñoz J; Megias D; Cascón A; Robledo M
Endocr Relat Cancer; 2013 Aug; 20(4):477-93. PubMed ID: 23660872
[TBL] [Abstract][Full Text] [Related]
12. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the insulin-like growth factor 1 receptor (IGF-1R) is associated with malignancy in familial pheochromocytomas and paragangliomas.
Fernandez MC; Martin A; Venara M; Calcagno Mde L; Sansó G; Quintana S; Chemes HE; Barontini M; Pennisi PA
Clin Endocrinol (Oxf); 2013 Nov; 79(5):623-30. PubMed ID: 23506534
[TBL] [Abstract][Full Text] [Related]
14. [Pheochromocytomas in adrenal medulla or extra-adrenal and multiple endocrine neoplasms:a clinicopathologic analysis of 181 cases].
Jiang CX; Zeng Z; Wang T; Liu X; Liu R; Li Y
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):762-6. PubMed ID: 22336161
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
16. PHOX2B is a Sensitive and Specific Marker for the Histopathological Diagnosis of Pheochromocytoma and Paraganglioma.
Miyauchi M; Akashi T; Furukawa A; Uchida K; Tamura T; Ando N; Kirimura S; Shintaku H; Yamamoto K; Ito T; Miura K; Kayamori K; Ariizumi Y; Asakage T; Kudo A; Tanabe M; Fujii Y; Ishibashi H; Okubo K; Murakami M; Yamada T; Takemoto A; Bae Y; Eishi Y; Ohashi K
Endocr Pathol; 2022 Dec; 33(4):506-518. PubMed ID: 36029394
[TBL] [Abstract][Full Text] [Related]
17. Pathology of pheochromocytoma and extra-adrenal paraganglioma.
Tischler AS; Kimura N; Mcnicol AM
Ann N Y Acad Sci; 2006 Aug; 1073():557-70. PubMed ID: 17102124
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma.
Ferrara AM; Lombardi G; Pambuku A; Meringolo D; Bertorelle R; Nardin M; Schiavi F; Iacobone M; Opocher G; Zagonel V; Zovato S
Anticancer Drugs; 2018 Jan; 29(1):102-105. PubMed ID: 29099418
[TBL] [Abstract][Full Text] [Related]
19. Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings.
Aygun N; Uludag M
Sisli Etfal Hastan Tip Bul; 2020; 54(2):159-168. PubMed ID: 32617052
[TBL] [Abstract][Full Text] [Related]
20. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.
Welander J; Söderkvist P; Gimm O
Endocr Relat Cancer; 2011 Dec; 18(6):R253-76. PubMed ID: 22041710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
